White Paper

Amanda Anderson, MSc, Sc.D.

Copyright 2024

Introduction

First, let me provide some context on my background. I hold a master’s degree in epidemiology and a doctorate in population health, and I have over 30 years of experience in the healthcare field. My work primarily analyzes and investigates health factors as a societal and environmental construct. Removing biases, I look at facts and peer-reviewed data, sift through research, and synthesize relevant information. In 2023, I published an epidemiological paper on global obesity and the social construct of unhealthy societies. The article, which takes a global perspective on factors contributing to the growing concern for metabolic diseases and long-term health outcomes, underscores the need for a comprehensive approach to address this curable disease. My professional opinion is that reducing obesity rates back to a level observed in the 60s and 70s benefits global societies across many spectrums, from health to economic growth. I am committed to finding effective strategies to achieve this. Recently, there has been a narrative circulating that obesity rates in the United States have declined, supposedly due to advances in medical treatments like GLP-1 receptor agonists, which are a class of medications used to manage diabetes and, more recently, obesity. However, a closer examination of the data reveals that this narrative is misleading. Not only do the latest reports from reputable sources like the CDC and Trust for America’s Health indicate that obesity rates have remained stable or even increased in many regions, but they also suggest that the pharmaceutical industry’s role in shaping this perception warrants a critical analysis, as it can lead to more effective public health strategies.

The narrative that obesity rates are declining, primarily due to the rise of GLP-1 receptor agonists, appears to be more a product of marketing than a reflection of reality. While these medications can be a valuable tool in the fight against obesity for some individuals, they are not a panacea for the more considerable public health challenge. To make lasting progress in reducing obesity rates, it is crucial to focus on comprehensive strategies that address both the biological and social determinants of health. The State of Obesity 2024 report provides a detailed look at the current state of obesity in the U.S. and the factors contributing to these trends.

The Reality Behind Obesity Statistics

Data from multiple health organizations, including the CDC, show that obesity rates have not decreased nationally. As of 2024, adult obesity rates are at or above 35% in 23 states, up from a decade ago when no state had such high rates. Severe obesity rates have also shown an upward trend, particularly among middle-aged adults and women. While some localized or short-term studies might suggest minor reductions in specific groups, these isolated cases do not indicate a broader national decline. Several factors contribute to the spread of the false narrative that obesity rates are declining. First, localized success stories are misinterpreted as national trends. Small-scale interventions, such as community health programs or state-level initiatives, have sometimes led to temporary reductions in obesity rates within specific populations. These successes, while valuable, are often generalized beyond their context, leading to a distorted perception of a nationwide improvement. The second is a misinterpretation of data. Changes in obesity rates are sometimes described as a reduction in the rate of increase rather than an actual decline. For example, if the rate at which obesity is growing slows down, some might mistakenly interpret this as a decline in obesity itself. This misunderstanding of the data creates a false sense of progress. Third, the pharmaceutical industry’s influence. There is growing speculation that the pharmaceutical industry plays a significant role in promoting the idea that obesity rates are declining, primarily to highlight the effectiveness of drugs like GLP-1 receptor agonists (e.g., liraglutide, semaglutide). While these medications have proven effective for some individuals in reducing weight, their impact is far from universal or sufficient to drive a nationwide decline in obesity rates. The focus on pharmacological solutions can overshadow the need for broader, more sustainable lifestyle changes and public health strategies.

The Role of GLP-1 Receptor Agonists in Shaping the Narrative

GLP-1 receptor agonists have shown promise in weight management by regulating blood sugar levels and appetite. They have become increasingly popular for treating obesity, leading to a surge in marketing and public relations efforts by pharmaceutical companies. However, attributing a national decline in obesity rates to these drugs alone is misleading for several reasons. First, these medications are typically prescribed to individuals with specific health conditions or those who can afford such treatments. Their high cost and the necessity of medical oversight limit widespread accessibility, which means their influence on broader population-level obesity rates remains minimal. Second, even among those who use GLP-1 receptor agonists, the effects on weight reduction may not be permanent. Once the medication is discontinued, weight regain is a common issue, indicating that these drugs do not address the root causes of obesity, such as dietary habits, physical inactivity, and socioeconomic factors. Third, the pharmaceutical industry has a vested interest in promoting these medications as a solution to the obesity epidemic. By shaping the narrative that these drugs can lead to a nationwide decline in obesity, they create a favorable market for their products, potentially at the expense of emphasizing non-pharmacological interventions like diet, exercise, and systemic policy changes. Notably, the media also plays a crucial role in amplifying this narrative. Positive news about breakthroughs in obesity treatment or isolated success stories often make headlines. In contrast, the underlying reality—that obesity rates continue to rise or remain stagnant in many areas—receives less attention. This selective focus creates a perception that significant progress is being made, which does not always align with the data. It’s essential to recognize that obesity is not solely a result of individual lifestyle choices but is influenced by structural and socioeconomic factors. Populations with limited access to healthy foods, safe spaces for physical activity, and adequate healthcare face more significant barriers to weight management. Unless these systemic issues are addressed, the idea of a substantial decline in obesity rates remains overly optimistic.

Fast Food and Manufacturing

The fast food industry and manufacturers could also have a vested interest in promoting the false narrative that obesity rates are declining. Both sectors have faced significant scrutiny and regulatory pressure due to their roles in the obesity epidemic. By supporting or amplifying claims of a decrease in obesity rates, these industries can potentially deflect criticism, reduce regulatory risks, and shift the focus away from calls for tighter controls on their products and marketing strategies. There may be reasons for pushing this false narrative. First, there are reasons for reputation management. Fast food chains and processed food manufacturers have long been criticized for their contributions to unhealthy diets. Promoting the idea that obesity rates are declining could be a way to rehabilitate their public image and portray themselves as part of the solution rather than the problem. Second is their influence on policy and regulation. If the public and policymakers believe that obesity rates are declining, there might be less urgency for implementing strict rules or public health interventions targeting these industries. This false sense of progress can delay efforts to introduce taxes on sugary drinks, more stringent labeling laws, or limits on advertising unhealthy foods to children. Third, their marketing strategies. Many fast food companies have started to market their healthier menu options, like salads or low-calorie meals, to appeal to health-conscious consumers. By aligning themselves with the idea that obesity rates are dropping, they can promote these products more effectively and shift consumer perception toward them as responsible, health-oriented brands. Fourth, a financial interest. The narrative benefits food manufacturers by maintaining consumer demand for their products. If obesity rates are falsely perceived to be declining, there may be less pressure on consumers to drastically change their eating habits, which could otherwise negatively impact sales. Finally, there is also the possibility of a coordinated narrative between food manufacturers and the pharmaceutical industry. As pharmaceutical companies promote drugs like GLP-1 receptor agonists as obesity treatments, it serves both parties’ interests to downplay the role of diet in obesity management. This partnership can deflect blame from the food industry’s contribution to obesity and frame the issue as a medical problem solvable with medication rather than lifestyle changes.

To effectively address the obesity crisis, a comprehensive approach is needed, one that goes beyond pharmaceutical solutions. Policy interventions that improve access to nutritious foods, promote physical activity, and reduce socioeconomic disparities are crucial. Public health messaging should shift from quick fixes to sustainable lifestyle changes supported by community-level programs and initiatives. If I am inaccurate with my assessment, then all the better for a healthy society is a prosperous society, but we must be true to data and biases.